Cholangiocarcinoma (CCA) Insights and Trends

• About 10,000 people in the United States develop cholangiocarcinoma each year.
• As per National Organization for Rare Disease (NORD), the incidence of intrahepatic CCA in the U.S. is approximately 1.50 per 100,000 people.  Recently, the incidence of bile duct cancers has been increasing. 
• Nearly two-thirds of patients with cholangiocarcinoma are aged 65 years or older at diagnosis, with the average age being around 70 years for intrahepatic bile duct cancer and 72 years for extrahepatic (perihilar or distal) disease.
• CCA accounts for ~10–15% of primary liver tumors and 3% gastrointestinal cancers.
• The highest incident cases of CCA were in the US, among the 7MM. 
• MRI/MRCP is considered the optimal initial imaging for suspected CCA due to superior biliary visualization.

Cholangiocarcinoma (CCA) Epidemiology Forecast in the 7MM

• 2025 CCA Incident Cases: XXX
• 2036 Projected CCA Incident Cases: XXX
• CCA Growth Rate (2026–2036): XXX%

DelveInsight's ‘Cholangiocarcinoma (CCA) Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the CCA, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Cholangiocarcinoma (CCA) Understanding and Diagnosis Algorithm

Cholangiocarcinoma (CCA) Overview and Diagnosis

CCA is a rare and aggressive malignancy arising from the epithelial cells of the bile ducts, which can occur within the liver (intrahepatic), at the hilum (perihilar), or outside the liver (distal). It is often diagnosed at an advanced stage due to non-specific early symptoms such as jaundice, abdominal pain, weight loss, and fatigue, leading to poor prognosis and limited curative options. The disease is also collectively referred to as biliary tract cancer (BTC), associated with significant clinical heterogeneity and high rates of recurrence even after treatment.

Further details are provided in the report.

Cholangiocarcinoma (CCA) Diagnosis

Diagnosis of CCA involves a combination of imaging, laboratory, and histopathological evaluation. Imaging modalities such as CT, MRI/MRCP, and ultrasound are used to identify tumor location and extent, while tumor markers like CA 19-9 may support suspicion but are not definitive. Confirmation is achieved through biopsy or cytology, and molecular profiling is increasingly used to identify actionable mutations such as FGFR2 fusions and IDH1 mutations to guide targeted therapy selection.

Further details are provided in the report.

Cholangiocarcinoma (CCA) Epidemiology

Key Findings from Cholangiocarcinoma (CCA) Epidemiological Analysis and Forecast 

• CCA most commonly occurs between the ages of 60 and 70 years.
• It is more frequently seen in males than females. 
• As per secondary analysis, the Incidence of CCA in Italy, Germany, UK and US is  ~3.4, ~3, ~2.2, and ~1.5 per 100,000 population. 
• CCA accounts for up to 15 % of primary hepatobiliary malignancies. In Europe, CCA incidence rates range from 0.4–1.8 per 100,000 population, while in the US, rates range from 0.6–1 per 100,000 population.
• In 2025, Germany recorded the highest number of incident CCA cases among the EU4 and UK countries. According to DelveInsight’s projections, this number is expected to increase by 2036. 

Scope of the Report

• The report covers a segment of a descriptive overview of CCA, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

Cholangiocarcinoma (CCA) Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of CCA? What will be the growth opportunities across the 7MM concerning the patient population with CCA?
• What is the historical and forecasted CCA patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.